Upgrade to SI Premium - Free Trial

Acadia Pharma (ACAD) Tops Q2 EPS by 7c; Raises FY Rev Guidance

July 31, 2019 4:09 PM
Acadia Pharma (NASDAQ: ACAD) reported Q2 EPS of ($0.38), $0.07 better than the analyst estimate of ($0.45). Revenue for the ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Earnings Guidance Management Comments

Next Articles